)
Ahmedabad-based pharma major Zydus Cadila has received the final approval from the US drug regulator to market Pyridostigmine Bromide Tablets USP, 60 mg.
The company said that the estimated sales in 2015 for Pyridostigmine Bromide Tablets USP which is used in the treatment of various neurological disorders is $ 27.9 million as per IMS.
The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.
